339
References
1. Remington, Sicence and Practice of Pharmacy, Published by
Wolters Kluwer Health (India) Pvt, Ltd, New Delhi, Volume I,
2007,495.
2. Mithal B.M, Text book of forensic pharmacy, Vallabh
Prakashan, 2003, 73.
3. Foye, W.O., (ed.), “Principles of Medicinal Chemistry”, 3rd Edn,
Varghese Company, Bombay, India, 1989, 26.
4. Wolff, M.E., (ed.), “Berger‟s Medicinal Chemistry”, 4th Edn, Wiley
Interscience, New York, 1981, 1.
5. Doserge, R.F. (ed.), “Wilson and Gisvold‟s Textbook of Organic,
Medicinal & Pharmaceutical Chemistry”, 8th Edn, Lippincott
Co., 1982, 1.
6. Korolkovas, A., “Essentials of Medicinal Chemistry”, 2nd Edn,
Wiley Interscience, New York, 1988, 3.
7. Goodman, A., and Gilman, Rall, T.W., Nies, A.S., and Taylor, P.,
“Goodman and Gilman‟s The Pharmacological Basis of
Therapeutics”, 8th Edn, Pergamon Press, New York, 1990, 45-
48.
8. The Drugs & Cosmetics Act & Rules, Government of India
Publications, 1984.
340
9. Indian Pharmacopoeia, Ministry of Health & Family Welfare,
Government of India, New Delhi, 1996.
10. British Pharmacopoeia, Convention Inc., Rockville, 2002.
11. British Pharmacopoeia, Her Majesty‟s Stationary Office, London,
2002.
12. Reynolds, J.E.F., “Martindale – The Extra Pharmacopoeia”, 33rd
Edn, The Pharmaceutical Press, London, 2002.
13. Chatten, L.G., (Ed. By), “Pharmaceutical Chemistry”, Vol. I and
II, Marcel Dekker Inc., New York, 1996, 1-2.
14. Beckett, A.H., and Stenlake, J.B., “Practical Pharmaceutical
Chemistry”, Vol. I and II, CBS Publishers & Distributors, New
Delhi, 1986, 2-5.
15. Sethi, P.D., “Quantitative Analysis of Drugs in Pharmaceutical
Formulations”, 3rd Edn, New Delhi, 1986, 1-2.
16. Willard, H.H., Merrit, L.L. Jr., Dean, J.A., and Settle, F.A. Jr.,
“Instrumental methods of analysis”, 6th Edn., CBS Publishers,
New Delhi, India,Year,1-6.
17. Day, R.A., and Underwood, A.L., “Quantitative Analysis”, 4th
Edn, Prentice Hall, New Delhi, 1986, 2-4.
341
18. Basett, J., Denney, R.C., Jerrery, G.H., and Mendham, J.,
“Vogel‟s Textbook of quantitative Inorganic Analysis”, 4th Edn,
Longman Group, England, 1986, 1-6.
19. Macek, T., and Kareel, D., “Pharmaceutical applications of thin-
layer and paper chromatography”, Elsevier Publishing
Company, Amsterdam, 1972.
20. Ramana Rao, G., Murthy, S.S.N., and Khadgapathi, P., “Gas
chromatography to pharmaceutical analysis (Review)”, Eastern
Pharmacist, 30 (353), 1987, 35.
21. Ramana Rao, G., Murthy, S.S.N., and Khadgapathi, P., “High
performance liquid chromatography and its role in
pharmaceutical analysis (Review)”, Eastern Pharmacist, 29
(346), 1986, 53.
22. Sastry, C.S.P., Prasad, T.N.V., and Rao, E.V., “Recent
application of high performance liquid chromatography in
pharmaceutical analysis (Review)”, Indian J. Pharm. Education,
21, 1987, 37.
23. Cheronics, N.D., and Ma, T.S., “Organic functional group
analysis by micro and semimicro methods”, Interscience, New
York, 1964.
24. Higuchi, T., and Brochman-Hausen, E., Pharmaceutical
Analysis, Edn, Interscience, London, 1961.
342
25. Siggia, S., and Hanna, J.G., “Quantitative organic analysis via
functional groups”, 4th Edn, Wiley-Interscience, Nottingholm,
1979.
26. Remington, Sicence and Practice of Pharmacy, Published by
Wolters Kluwer Health (India) Pvt, Ltd, New Delhi, Volume I,
2007, 1556-1570.
27. Salmon, S. E. and Sartorelli, A. C. Cancer Chemotherapy, in
Basic and Clinical Pharmacology, (Katzung, B. G., Ed) Appleton-
Lange, 1998, 881-911.
28. Besthron, E., Ber. Otsch. Chem. Ges., 43, 1910, 1519.
29. Huning, S., and Fritsch, K.H., Ann. Chem., 609, 1957, 143 and
172.
30. Huning, S., Balli, H., Briether, E., Bruhne, F., Geiger, H.,
Grigat, E., Muller, F., and Quast, H., Angew. Ann.Chem, 74,
1962, 818.
31. Sawicki, E, Hauser, T.R., Stanley, T.W., and Elbert, W., Anal.
Chem., 33, 1961, 93.
32. Sawicki, E., Schumachar, R., and Engel, C.R., Microchem. J.,
12, 1967, 377.
33. Hauser, T.R., and Cummins, R.L., Anal. Chem., 36, 1964, 679.
34. Alshuller, A.P., and Leng, L.J., Anal. Chem., 35, 1963, 1541.
343
35. Kamata, E., Bull. Chem. Soc., Japan, 38, 1965, 2005.
36. George, J.N., Anal. Chem., 53, 1981, 1708.
37. Cohen, I.R., and Altshuller, A.P., Annal. Chem., 38, 1966, 1418.
38. Davis, R.P., and Janis, R., Nature, 210, 1966, 318.
39. Pays, M., Malargean, R., and Bourdon, R., Ann. Pharm. Fra.,
24, 1966, 763.
40. Soda, K., Yorifuji, T., Misono, H., and Moriguchi, M., Biochem.
J., 114, 1969, 629.
41. Newman, F.W., Anal. Chem., 47, 1969, 2077.
42. Umeda, M., Yakugaku Zasshi, 83, 1963, 951.
43. Kamata, E., Bull. Chem. Soc., Japan, 37, 1964, 1674.
44. Pays, M., and Boudon, R., Ann. Pharm. Fr., 20, 1968, 681.
45. Sastry, C.S.P., Sankar, D.G., Reddy, M.N., and Singh, N.R.P.,
Indian Drugs, 25, 1988, 130.
46. Friestad, H.O., Ott. D.E., Gunther, F.A., Anal Chem., 43, 1969,
1750.
47. Pays, M., and Baljean, M., Ann. Pharm. Fr., 28, 1970,153.
48. Sawicki, E., Hauser, T.R., Stanley, T.W., and Elbert, W., Anal.
Chem., 33, 1961, 93.
344
49. Sawicki, T.W., Stanely, Hauser, T.R., Elbert, W. and Noe, J.L.,
Anal. Chem., 33, 1961, 722.
50. Sastry, C.P.S., Tirupathi Rao, T., and Sailaja, A., Talanta, 38,
1991, 1057.
51. Pays, M., Bourdon, R., and Beljean, M., Anal. Chem. Acta., 47,
1969,101.
52. Sawicki, E., Hauser, T.R., Stanely, T.W., Elbert, W., and Fox,
F.T., Anal Chem., 33, 1961, 1574.
53. Fog, J., and Jellum, E., Nature, 195, 1962, 490.
54. Pays, M., Ann. Pharm. Fr., 25, 1967, 29.
55. Hurst, E.R., Saltine, M.J., Anal. Biochem, 115, 1981, 88.
56. Kommons, E., and Micheal, E., Arch. Pharm. Chem. Sci. Ed.,
10, 1982, 146.
57. Persey, M., and Baltos, J., Ann. Pharm. Fr., 28, 1970, 153.
58. Serbbort, W.S., Photogr. Sci., 17, 1969, 13.
59. Sastry, C.S.P. and Sastry, B.S, The Eastern Pharmacist, 29
(345), 1986, 31.
60. Wesp, E.F., and Brode, W.R., J. Am. Chem. Soc., 56, 1934,
1037.
61. Iami, K., Yamada, S., Kubata, H., and Sakamaki, J. Eur. Pat.
Appl., 17 (1964); Chem. Abstr., 94, 1981, 9932f.
345
62. Besada, A., Anal. Lett, 20, 1987, 427.
63. Chowdhary, K.P.R., and Rao, G.D., Indian Drugs, 34(5), 1997,
283.
64. Sastry, C.S.P., Sankar, D.G., Reddy, M.N., and Aruna, M.,
Indian J. Pharm. Sci., 50, 1988,178.
65. Tren, C.C., Anal. Chem., 33, 1961, 849.
66. Collins, P.F., Diehl, H., and Frederick Smith, G., Anal. Chem.,
31, 1959, 1862.
67. Raggi, M.A., Cavrini, A.M., Di Pietra, and Lacche, D., Pharm.
Acta. Hel, 63, 1988, 19.
68. Barta, L., Biochem. Z., 274, 1934, 212.
69. Berrenscheen, H.K., and Dreguss, M., Ibid, 3, 1931, 305.
70. Lappin, G.R., and Clark, L.C., Anal. Chem., 23, 1951,541.
71. Mathewson, W.C., J. Am. Chem. Soc., 42, 1920, 1277.
72. Matheissen, G., and Dahn, H., Z. Ger. Exp. Med., 113, 1944,
336.
73. Pool, M.F., and Klose, A.A., J. Am. Oil. Chem. Soc., 28, 1945,
215.
74. Kirk, G.F., Bright, Talanta, 13, 1966, 1.
75. Pattergill, M.D., and Sands, D.E., J. Chem. Educ., 58, 1979,
244.
346
76. Sandell, E.B., “Colorimetric determination of traces of metals”,
Interscience, New York, 1950.
77. Ayres, G.H., Anal. Chem., 21, 1949, 652.
78. Guide for the use of terms in reporting data, Anal. Chem., 54,
1982,157.
79. Massart, D.L., Vandeginste, B.G.M., Deming, S.N., Michotte, Y.,
and Kaufman, L., “Chemometrics: A Textbook”, Elsevier,
Amsterdam, 1988.
80. Indian Pharmacopoeia, Ministry of Health & Family Welfare,
Government of India, New Delhi, Volume 2,2007,1243.
81. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal
Pharmaceutical Society, 1996, 580-81.
82. Yang X, Hu Z, Chan SY, Goh BC, Duan W, Chan E and Zhou S,
“Simultaneous determination of the lactone and carboxylate
forms of irinotecan (CPT-11) and its active metabolite SN-38 by
high-performance liquid chromatography: application to plasma
pharmacokinetic studies in the rat”, J Chromatogr B Analyt
Technol Biomed Life Sci., 821(2),2005,221-8.
83. Poujol S, Pinguet F, Malosse F, Astre C, Ychou M, Culine S and
Bressolle F, “Sensitive HPLC-fluorescence method for irinotecan
and four major metabolites in human plasma and saliva:
347
application to pharmacokinetic studies”, Clin Chem.,
49(11),2003,1900-8.
84. Jong FA De, Mathijssen RH, Bruijn P de, Loos WJ, Verweij J
and Sparreboom A, ”Determination of irinotecan (CPT-11) and
SN-38 in human whole blood and red blood cells by liquid
chromatography with fluorescence detection”, J Chromatogr B
Analyt Technol Biomed Life Sci, 795(2), 2003,383-8.
85. Schoemaker NE, Rosing H, Jansen S, Schellens JH and Beijnen
JH, “High-performance liquid chromatographic analysis of the
anticancer drug irinotecan (CPT-11) and its active metabolite
SN-38 in human plasma”,Ther Drug Monit,25(1), 2003,120-4.
86. Rivory LP and Robert J, “Identification and kinetics of a beta-g
glucuronide metabolite of SN-38 in human plasma after
administration of the camptothecin derivative irinotecan”, J
Chromatogr B Biomed Appl, 36 (2), 1995, 176-9.
348
87. Barilero I, Gandia D, Armand JP, Mathieu-Boue A, Re
M,Gouyette A and Chabot GG, “Simultaneous determination of
the camptothecin analogue CPT-11 and its active metabolite
SN-38 by high-performance liquid chromatography: application
to plasma pharmacokinetic studies in cancer patients”, J
Chromatogr, 575 (2),1992, 275-80.
88. Sastry C.S.P, Reddy B.S and Mangala D.S, Indian Drugs, 21,
1984,526.
89. Das Gupta V., Indian J.Pharm, 35, 1973, 77.
90. Shingbal D.M, Ibid, 35, 1973,160.
91. Kyoji T, Shoh M and Toru U, Talanta, 29, 1982,103.
92. Reddy B.S and Sastry C.S.P, J.Inst.Of Chemists, (India), 5,
1983, 69.
93. Sastry B.S, Rao E.V, Tummuru M.K and Sastry C.S.P, Indian
Drugs, 24, 1986,105.
94. Viswanadham N, Reddy M.N and Sastry C.S.P, Indian
J.Pharm.Sci, 45, 1983, 81.
95. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal
Pharmaceutical Society, 1996, 545.
96. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,
J.O.Neil, Merck Research lab, division of Merck & Co., NJ,
2006, monograph no.1200,1203.
349
97. Singh AK, Chaurasiya A, Jain GK, Awasthi A, Asati D, Mishra
G, Khar RK, Mukherjee R.,"High performance liquid
chromatography method for the pharmacokinetic study of
bicalutamide SMEDDS and suspension formulations after oral
administration to rats",Talanta,78(4-5),2009,1310-4
98. Nageswara Rao R, Narasa Raju A, Narsimha R, J Pharm Biomed
Anal,”Isolation and characterization of process related
impurities and degradation products of bicalutamide and
development of RP-HPLC method for impurity profile study”,
46(3), 2008,505-19.
99. Nageswara Rao R, Narasa Raju A, Nagaraju D,”An improved and
validated LC method for resolution of bicalutamide enantiomers
using amylose tris-(3,5-dimethylphenylcarbamate) as a chiral
stationary phase”,J Pharm Biomed Anal, 42(3),2006,347-53.
100. Török R, Bor A, Orosz G, Lukács F, Armstrong DW, Péter A.,
High-performance liquid chromatographic enantioseparation of
bicalutamide and its related compounds,J Chromatogr A.
,1098(1-2), 2005,75-81.
101. Sancheti P. P, Vyas V. M., Manali Shah, Poonam Karekar and
Pore Y. V.,"Spectrophotometric Estimation of Bicalutamide in
Tablets", Indian J. Pharm. Sci., 70 (6), 2008, 810-812.
350
102. Xu LX,Shen YX,Wang HY,Jiang JG, Xiao Y, "Spectrophotometric
determination of procaine hydrochloride in pharmaceutical
products using 1,2-naphthoquinone-4-sulfonic acid as the
chromogenic reagent", Spectrochim Acta A Mol Biomol
Spectrosc,59(13),2003,3103-10.
104. Martindale, “The Complete Drug Reference”, Edited by Sean C
Sweetman, 34th Edition, 2005, p.557.
105. Farhan H, Wahala K, Cross HS,” Genistein inhibits vitamin D
hydroxylases CYP24 and CYP27B1 expression in prostate cells”,
J Steroid Biochem Mol Biol, 84(4), 2003,423-9.
106. Charles GD, Bartels MJ, Zacharewski TR, Gollapudi BB,
Freshour NL, Carney EW, “Activity of benzo[a]pyrene and its
hydroxylated metabolites in an estrogen receptor-alpha reporter
gene assay”, Toxicol Sci,55(2),2000, 320-6.
106. Zalcberg JR, Hu XF, Ching M, Wakeling A, Wall DM, Marschner
IC, Luise M de ,” Differential effects of estrogen, tamoxifen and
the pure antiestrogen ICI 182,780 in human drug-resistant
leukemia cell lines “,Cancer Chemother Pharmacol., 33,
1993,123.
107. Sivasubramanian Lakshmi., Mervin Arul, M., Jayasankar, L
Ramu, Indian. J.Pharm. Sci, 66, 2004,249.
108. Vadia NH, Patel VB, Indian J Pharm Sci, 68, 2006,584.
351
109. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,
J.O.Neil, Merck Research lab, division of Merck & Co., NJ,
2006, monograph no.4902,4905.
110. Oostendorp RL, Beijnen JH, Schellens JH, Tellingen O,
“Determination of imatinib mesylate and its main metabolite
(CGP74588) in human plasma and murine specimens by ion-
pairing reversed-phase high-performance liquid
chromatography”, Biomed Chromatog, 21(7), 2007, 747-54.
112. Guetens G, Prenen H, Boeck G De, Oosterom A van,Schöffski P,
Highley M, Bruijn EA de,” Simultaneous determination of
AMN107 and Imatinib (Gleevec,Glivec,STI571) in cultured tumour
cells using an isocratic high-performance liquid chromatography
procedure with UV detection”, J Chromatogr B Analyt Technol
Biomed Life Sci,846(1-2), 2007,341-5.
113. Titier K, Picard S, Ducint D, ETeilhet , Moore N, Berthaud P,
Mahon FX, Molimard M,” Quantification of imatinib in human
plasma by high-performance liquid chromatography-tandem
mass spectrometry”,Ther Drug Monit,27(4), 2005,634-40.
114. Widmer N,Béguin A, Rochat B, Buclin T, Kovacsovics T,
Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA,”
Determination of imatinib (Gleevec) in human plasma by solid-
phase extraction-liquid chromatography-ultraviolet absorbance
352
detection”, J Chromatogr B Analyt Technol Biomed Life Sci,
803(2), 2004,285-92.
115. Ivanovic D, Medenica M, Jancic B,Malenovic A,” Reversed-
phase liquid chromatography analysis of imatinib mesylate and
impurity product in Glivec capsules”,J Chromatogr B Analyt
Technol Biomed Life Sci,800(1-2), 2004,253-8.
116. Bende G, Kollipara S, Sekar V, Saha R,"UV-spectrophotometric
determination of imatinib mesylate and its application in
solubility studies",Pharmazie,63(9),2008,641-5.
117. Martindale, The Complete Drug Reference, Edited by Sean C
Sweetman, 34th Edition, 2005, p.557.
118. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,
J.O.Neil, Merck Research lab, division of Merck & Co., NJ,
2006, monograph no.4379,4377.
119. Puhringer-Oppermann FA, Stein HJ, Sarbia M, Dis
Esophagus, 20, 2007.
120. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J,
Barnett S,Guilbaud PG, Stephens TC,Mol Cancer Ther., 4,2005.
121. McKillop D, McCormick AD, Miles GS, Phillips PJ, Pickup KJ,
Bushby N, Hutchison M, Xenobiotica, 34, 2004.
122. Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M,
Baker SD, “Specific method for determination of gefitinib in
353
human plasma, mouse plasma and tissues using high
performance liquid chromatography coupled to tandem mass
spectrometry”, J Chromatogr B Analyt Technol Biomed Life Sci.,
819(1), 2005,73-80.
123. Jones HK, Stafford LE, Swaisland HC, Payne R, J Pharm
Biomed Anal., “A sensitive assay for ZD1839 (Iressa) in human
plasma by liquid-liquid extraction and high performance liquid
chromatography with mass spectrometric detection: validation
and use in Phase I clinical trials”, 29(1), 2002,221-8.
124. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,
J.O.Neil, Merck Research lab, division of Merck & Co., NJ,
2006, monograph no.1754,1753.
125. Dhananjeyan MR, Liu J, Bykowski C, Trendel JA et.al, “Rapid
and simultaneous determination of capecitabine and its
metabolites in mouse plasma, mouse serum, and in rabbit bile
by high-performance liquid chromatography”, J Chromatogr A.,
1138(1-2), 2007, 101-8.
126. Guichard SM, Mayer I, Jodrell DI, J Chromatogr B Analyt
Technol Biomed Life Sci., 826, 2005,232.
127. Li KM, Rivory LP, Clarke SJ, J Chromatogr B Analyt Technol
Biomed Life Sci., 820, 2005,121.
354
128. Siethoff C, Orth M, Ortling A, Brendel E, Wagner-Redeker W,
“Simultaneous determination of capecitabine and its metabolite
5-fluorouracil by column switching and liquid
chromatographic/tandem mass spectrometry”, J Mass
Spectrom., 39(8), 2004,884-9.
129. Zufía L, Aldaz A, Giráldez J, “Simple determination of
capecitabine and its metabolites by liquid chromatography with
ultraviolet detection in a single injection”, J Chromatogr B
Analyt Technol Biomed Life Sci., 809(1), 2004, 51-8.
130. Xu Y, Grem JL, “Liquid chromatography-mass spectrometry
method for the analysis of the anti-cancer agent capecitabine
and its nucleoside metabolites in human plasma”, J
Chromatogr B Analyt Technol Biomed Life Sci., 783(1), 2003,
273-85.
132. Vanitha Prakash K, Venkateswara Rao J,Appala Raju
N,”Validated Reverse Phase HPLC method for the determination
of capecitabine in pharmaceutical dosage forms”, Oriental
Journal of Chemistry, 24, 2008,335.
133. Sethi P.D, High Performance Liquid Chromatography,
Quantitative Analysis of Pharmaceutical Formulations, CBS
Publishers & Distributors, 2001, 3.
355
134. Skoog D.A., Holler F.J., and Nieman, T.A., Principles of
Instrumental Analysis, 5th Edn, 1997.
135. Jansson, S.O., and. Johansson, S., J.Chromatogr. 1982, 242,
41.
136. Heftmann, E., Ed., Chromatography, 5th Ed., Elsevier,
Amsterdan, 1992.
137. Poole, C.F., and Poole S.K., Chromatography, Today Elsevier,
Amsterdan, 1991.
138. Grob, R.L., Ed., Modern practice of Gas Chromatography, 3rd
edn, Wiley-Interscience, New York, 1995.
139. Weinberger, R., Practical Capillary Electrophoresis, Academic
press, San Dioego. CA, 1993.
140. Kirchner, J.G., Thin-Layer Chromatography, 2nd Edn., Wiley-
Interscience, New York, 1978.
141. Lee, M.L., and Markides K.E., eds., Analytical Supercritical
Fluid Chromatography and Extraction Chromatography
Conferences, Inc., Provo. UT. 1990.
142. Small, H., Ion Chromatography, Plenum, New York, 1989.
143. Yau, W.W., Kirkland, J.J., and Bly, D.D., Modern Size-
Exclusion Liquid Chromatography, Wiley-Interscience, New
York 1979.
144. Braumann, T., Weber, G., and Grimme L.H., J. Chromatogr.,
1983, 261, 329.
145. Snyder, L.R., Dolan, J.W., and Rommen, D.C., J. Chromatogr.,
1989, 485, 91.
146. Dolan, J.W., Lommen, D.C., and Snyder, L.R., J.Chromatogr.,
1989, 485, 91.
356
147. Li, Z., Rutan, S.C., and Dong, S., Anal. Che., 1996, 68, 124.
148. Dolan, J.W., and Snyder, L.R., Trouble Shooting LC System,
Humana Press, Totowa, N.J., 1989.
149. USP 31/NF 26, Asian Edition, United States Pharmacopoeia
Convention, Volume 1, 2008,684.
150. Validation of Analytical Methods: Definitions and Terminology,
ICH Harmonised Tripartite Guideline, ICH Topic Q2A, 1994.
151. Validation of Analytical Procedures,Methodology, Step 4,
Consensus,ICH Harmonised Tripartite Guideline, ICH Q2 B.
1996.
152. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal
Pharmaceutical Society, 1996, 604.
153. rd KE, Schaiquevich P, Bai F, Fraga CH, Miller L, Panetta JC,
Stewart CF, “Application of a highly specific and sensitive
fluorescent HPLC method for topotecan lactone in whole blood”,
23(7),707-13, 2009.
154. de Vries NA, Ouwehand M, Buckle T, Beijnen JH, van Tellingen
O,”Determination of topotecan in human and mouse plasma
and in mouse tissue homogenates by reversed-phase high-
performance liquid chromatography“,Biomed
Chromatogr.,21(11),2007,1191-200.
155. Gravel E, Bourget P, Mercier L, Paci A,"Fluorescence detection
combined with either HPLC or HPTLC for pharmaceutical
357
quality control in a hospital chemotherapy production unit:
application to camptothecin derivatives"J Pharm Biomed
Anal.,39(3-4),2005,581-6.
156. Vali AM, Shafaghi B, Dadashzadeh S,"Simple and sensitive high
performance liquid chromatographic method for the
simultaneous quantitation of the lactone and carboxylate forms
of topotecan in human plasma",J Chromatogr B Analyt Technol
Biomed Life Sci,818(2),2005,205-12.
157. Chen J, Balthasar JP,"High-performance liquid
chromatographic assay for the determination of total and free
topotecan in the presence and absence of anti-topotecan
antibodies in mouse plasma",J Chromatogr B Analyt Technol
Biomed Life Sci,816(1-2),2005,183-92.
158. Bai F, Kirstein MN, Hanna SK, Iacono LC, Johnston B, Stewart
CF,"Determination of plasma topotecan and its metabolite N-
desmethyl topotecan as both lactone and total form by reversed-
phase liquid chromatography with fluorescence detection",J
Chromatogr B Analyt Technol Biomed Life Sci,784(2),2003,225-
32.
159. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal
Pharmaceutical Society, 1996, 544.
358
160. M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker
SD,"Quantification of 5-azacytidine in plasma by electrospray
tandem mass spectrometry coupled with high-performance
liquid chromatography",J Chromatogr B Analyt Technol Biomed
Life Sci,813(1-2),2004,81-8.
161. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan
KK,"Characterization of decomposition products and preclinical
and low dose clinical pharmacokinetics of decitabine (5-aza-2'-
deoxycytidine) by a new liquid chromatography/tandem mass
spectrometry quantification method",Rapid Commun Mass
Spectrom, 20(7), 2006, 1117-26.
162. Rustum AM, Hoffman NE,"High-performance liquid
chromatographic determination of 5-azacytidine in plasma", J
Chromatogr, 421(2), 1987, 387-91.
163. Lin KT, Momparler RL, Rivard GE, "Sample preparation for the
determination of 5-aza-2'-deoxycytidine in plasma by high
performance liquid chromatography", J Chromatogr, 345(1),
1985, 162-7.
164. Galushko SV, Shishkina IP, "Reversed-phase ion-paired high-
performance liquid chromatographic determination of 6-
azacytidine in blood", J Chromatogr, 345(1), 1985, 157-61.
359
165. McMaster, Marvin C. (2005). LC/MS: a practical user's guide.
New York: John Wiley. ISBN 0-471-65531-7.
166. Wilfried M.A. Niessen, Wilfried M. Niessen (2006). Liquid
Chromatography-Mass Spectrometry, Third Edition
(Chromatographic Science). Boca Raton: CRC. ISBN 0-8247-
4082-3.
167. ThurmanE.M,Ferrer,Imma(2003). Liquid chromatography/mass
spectrometry, MS/MS and time of flight MS: analysis of
emerging contaminants. Columbus, OH: American Chemical
Society. ISBN 0-8412-3825-1.
168. Ardrey, R. E.; Ardrey, Robert (2003). Liquid chromatography-
mass spectrometry: an introduction. London: J. Wiley. ISBN 0-
471-49801-7.
169. Yergey, Alfred L. (1990). Liquid chromatography/mass
spectrometry: techniques and applications. New York: Plenum
Press. ISBN 0-306-43186-6.
170. U.S .Department of Health and Human Services, Food and Drug
Administration., Guidance for Industry, Bioanalytical
Method Validation, May2001.
171. Nowatzke W, Woolf E, Best Practices during Bioanalytical
Method Validation for the Characterization of Assay Reagents
and the Evaluation of Analyte Stability in Assay Standards,
360
Quality Controls, and Study Samples, AAPS Journal. 9(2), 2007,
E117-E122.
172. Braggio S, Barnaby R.J, Grosi P , Cugola M, A strategy for
validation of bioanalytical methods,Journal of Pharmaceutical
and Biomedical Analysis 1996, 14, 375- 388.
173. Boulanger B. , Chiap P. Dewe W., Crommen J., Hubert Ph., An
analysis of the SFSTP guide on validation of chromatographic
bioanalytical methods: progresses and limitations Journal of
Pharmaceutical and Biomedical Analysis,32, 2003,753-765.
174. Causon Roger, Validation of chromatographic methods in
biomedical analysis viewpoint and discussion, Journal of
Chromatography B, 689 (1997) 175-180.
175. Hartmann C., Smeyers-Verbeke J., Massart D. L., McDowall
R.D., Validation of bioanalytical chromatographic methods,
Journal of Pharmaceutical and Biomedical Analysis17,
1998,193–218.
176. Kelley M, DeSilva, B.,Key Elements of Bioanalytical Method
Validation for Macromolecules., AAP Journal. 2007, 9(2), E156-
E163.
177. Albano J, Howell A. Robertson JFR, Quaresma. “Fulvestrant is
as effective as anastrozole in postmenopausal women with
361
advanced breast cancer progressing, after prior endocrine
treatment.” J. Clinical Oncology, 20, 2002, 3396-3403.
178. Brunner N Coopman P, Garcia M, “Anti-proliferative and anti-
estrogenic effectsof ICI 164,384 and ICI 182,780 in 4-OH-
tamoxifen-resistant Rabbit breast-cancercells.”,International
Journal of Cancer 56, 1994,295-300.
179. Gee J, Robertson J, Nicholson R., “The Pharmacokinetics of
single-dose FaslodexTM (ICI 182,780) in post-menopausal
primary breast cancer; relationship with estrogen receptor(ER)
down-regulation”, [abstract no.362]. Process American Society
Clinical Oncology, 19, 2000, 94A.
180. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780
(Faslodex): “Development of a novel, “pure” antiestrogen.”,
Cancer, 89, 2000, 817.
181. Jordan VC, Murphy CS.”Endocrine pharmacology of
antiestrogens as antitumor agents.” Endocr Rev., 11, 1990,578-
610.
182. Lykkesfeldt AE. “Mechanisms of tamodifen resistance in the
treatment of advanced breast cancer.”, Acta Oncology.,
35(Suppl-5), 1996, 9-14.
183. Robertson JR, Howell A. DeFeriend DJ. “Pharmacokinetics
pharmacological and anti-tumor effects of the specific anti-
362
oestrogen in women with advanced breast cancer.”, British
Journal of Cancer,74, 1996,300-308.
184. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP and
Yacobi A et al. Analytical methods validation: bioavailability,
bioequivalence and pharmacokinetic studies Conference report,
European Journal of Drug Metabolism and Pharmacokinetics,
16, 1991,249.
185. Wakeling AE.,”The future of new pure antiestrogens in clinical
breast cancer. Breast Cancer Research and Treatment.” 25,
1993, 1-9.